Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size From 2025 to 2034?
The market size of sodium glucose cotransporter 2 (sglt2) inhibitors has demonstrated robust growth in the recent past. The projected expansion indicates an increase from $10.17 billion in 2024 to $10.96 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The significant growth in previous periods may be accounted for by successful early clinical trials, a surge in regulatory approvals, a rise in diagnoses of diabetes, and an increasing demand for novel diabetes therapies.
The market size for sodium glucose cotransporter 2 (sglt2) inhibitors is projected to experience significant growth in the upcoming years, estimated to reach a value of $15.09 billion by 2029, with a compound annual growth rate (CAGR) of 8.3%. This expected growth during the forecast period can be linked to a surge in diabetes cases, an increase in obesity rates, heightened public awareness about diabetes management, and its increasing use in treating heart and kidney diseases. Some of the major forthcoming trends include the incorporation of combination treatments, the use of personalized medicine, advancements in technology, and conventional drug creation.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
What Are the Core Growth Drivers Propelling the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forward?
The sodium glucose cotransporter 2 (SGLT2) inhibitor market is projected to expand due to the escalating occurrence of diabetes. Diabetes is a collection of metabolic disorders identified by excessive sugar levels in the blood caused by defects in insulin production, function, or both. The development of diabetes can be due to various factors including urbanization, stress, environmental pollution, and limited access to medical services. SGLT2 inhibitors, used in the treatment of diabetes, lower blood glucose levels by hindering glucose reabsorption in the kidneys, which results in glucose being excreted in the urine. These inhibitors present cardiovascular and renal advantages, making them an effective solution for managing diabetes and related complications. As an example, in December 2023, as per the Australian Bureau of Statistics, a government agency in Australia, it was reported that in 2022, about 1.3 million people, or 5.3% of Australians, were diagnosed with diabetes with similar rates among males (5.8%) and females (4.9%). The occurrence of diabetes has been on a steady rise, substantially increasing with age, peaking at 18.7% in those aged 75 and beyond. Among the types of diabetes, type 2 is the most prevalent, making up 87.6% of all cases. Additionally, factors like being born overseas, residing in underprivileged areas, and living with a disability are linked with increased diabetes instances. Therefore, the surge in diabetes prevalence is a key growth driver for the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
What Segment Types Define the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Structure?
The sodium glucose cotransporter 2 (sglt2) inhibitorsmarket covered in this report is segmented –
1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
2) By Route Of Administration: Oral Route; Other Route Of Administration
3) By End User: Hospitals; Homecare Settings; Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theSodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry Evolution?
Leading companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are keen on advancing dual inhibitor therapeutic approaches to optimize patient results and regulate blood sugar concentrations. Dual inhibitor therapeutic options are methods that concurrently target two disparate sodium-glucose cotransporters (SGLT1 and SGLT2) to boost efficiency in dealing with conditions like heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., an American biopharmaceutical enterprise, obtained approval from the Food and Drug Administration (FDA) for sotagliflozin, a medication for heart failure. This pioneer, a dual inhibitor of sodium-glucose cotransporters 1 and 2, is a once-daily tablet configured to minimize cardiovascular death, hospitalizations due to heart failure, and urgent heart failure appointments in adults with heart failure, type 2 diabetes, chronic kidney illness, and other cardiovascular risk factors. Advantages include diminished renal glucose and sodium reabsorption, which results in the reduction of preload and afterload and reduced sympathetic activity.
View the full report here:
What Is the Definition of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
